香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited 兆科眼科有限公司 主 席 李小羿博士 （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 香 港，2025年8月14日 （股份代號：6622） 於 本 公 告 日 期，本 公 司 董 事 會 包 括 執 行 董 事 李 小 羿 博 士 及 戴 向 榮 先 生；非 執 行 董 事 李 燁 妮 女 士 及 張 甜 甜 女 士；以 及 獨 立 非 執 行 董 事 黃 顯 榮 先 生、盧 毓 琳 教 授 及 劉 懷 鏡 先 生。 董事會會議通告 兆 科 眼 科 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於2025年8月28日（星 期 四）舉 行，以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬 公 司 ...

Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622), has seen a significant stock price increase of over 35% this week, with a current price of HKD 3.78 and a trading volume of HKD 22.5882 million, following the announcement of obtaining a medical device registration certificate for TONO-i from the National Medical Products Administration of China [1] Group 1: Product Development - The TONO-i device will be a crucial part of the company's glaucoma medical product portfolio, addressing the demand gap in China for low diagnosis and treatment rates [1] - TONO-i provides ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, which aids in delivering immediate and continuous feedback on treatment efficacy, thereby improving patient compliance with glaucoma medication [1] - The introduction of TONO-i into the company's pipeline signifies its commitment to a dual approach in glaucoma management, focusing on both treatment and diagnosis [1] Group 2: Distribution Agreement - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of developing diagnostic, therapeutic, and preventive medical devices for glaucoma [1] - Under the terms of the agreement, the company holds exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, which were later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 7% and nearly 35% this week, indicating strong market interest and confidence in the company's future prospects [1] Company Developments - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, which will be a key part of its glaucoma medical product portfolio [1] - TONO-i is designed to provide ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, thereby improving patient adherence to glaucoma medication treatment [1] - The introduction of TONO-i into the company's pipeline underscores its commitment to dual approaches in glaucoma management, focusing on both treatment and diagnosis [1] Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of glaucoma diagnostic, treatment, and prevention medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

Core Viewpoint - The company, Zhaoke Ophthalmology-B (6622.HK), has seen a significant stock price increase of 17.36%, reaching HKD 3.65, potentially marking a new closing high since January 4, 2024 [1] Group 1: Product Development - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, which will be a key part of its glaucoma product portfolio [1] - TONO-i aims to address the demand gap in China for low diagnosis and treatment rates in glaucoma management, indicating the company's commitment to dual approaches in treatment and diagnosis [1] Group 2: Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the development of medical devices for the diagnosis, treatment, and prevention of glaucoma [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

消息面上，兆科眼科发布公告，公司已向国家药品监督管理局取得TONO-i的医疗器械注册证。TONO-i 将作为公司旗下青光眼医疗产品组合的重要部分，满足中国低诊断及治疗比率的需求缺口。TONO-i为 眼科医生提供一种工具，透过测量轻易、准确及透彻地监察患者的眼压，有助患者提供疗效的即时及持 续反馈，提高患者青光眼药物治疗的依从性。 兆科眼科-B(06622)再涨超10%，截至发稿，涨9.32%，报3.4港元，成交额1132.54万港元。 值得注意的是，2022年11月，公司与C&VTech达成一项有关TONO-i的独家分销协议。C&VTech为一间 于开发诊断、治疗及预防青光眼的医疗器材领域具有领先地位的公司。根据该协议的条款，公司拥有于 大中华登记、进口、推广、分销、营销及出售TONO-i的独家权利。该等权利其后透过合约修订扩大至 包括泰国及马来西亚，自2024年8月起生效。 ...

值得注意的是，2022年11月，公司与C&VTech达成一项有关TONO-i的独家分销协议。C&VTech为一间 于开发诊断、治疗及预防青光眼的医疗器材领域具有领先地位的公司。根据该协议的条款，公司拥有于 大中华登记、进口、推广、分销、营销及出售TONO-i的独家权利。该等权利其后透过合约修订扩大至 包括泰国及马来西亚，自2024年8月起生效。 智通财经APP获悉，兆科眼科-B(06622)再涨超10%，截至发稿，涨9.32%，报3.4港元，成交额1132.54万 港元。 消息面上，兆科眼科发布公告，公司已向国家药品监督管理局取得TONO-i的医疗器械注册证。TONO-i 将作为公司旗下青光眼医疗产品组合的重要部分，满足中国低诊断及治疗比率的需求缺口。TONO-i为 眼科医生提供一种工具，透过测量轻易、准确及透彻地监察患者的眼压，有助患者提供疗效的即时及持 续反馈，提高患者青光眼药物治疗的依从性。 ...

Core Viewpoint - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, marking a significant advancement in its glaucoma product portfolio [1] Group 1: Product Overview - TONO-i is an innovative, non-contact, portable, and lightweight tonometer designed for painless and infection-free use without anesthesia [1] - The device aims to address the low diagnosis and treatment rates for glaucoma in China, providing a crucial tool for ophthalmologists to monitor patients' intraocular pressure accurately and continuously [1] Group 2: Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&V Tech, a leading company in the field of glaucoma diagnostic, treatment, and prevention medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]

TONO-i将作为公司旗下青光眼医疗产品组合的重要部分，满足中国低诊断及治疗比率的需求缺口。 TONO-i为眼科医生提供一种工具，透过测量轻易、准确及透彻地监察患者的眼压，有助患者提供疗效 的即时及持续反馈，提高患者青光眼药物治疗的依从性。TONO-i加入公司的管线，标志着公司在治疗 及诊断双管齐下的青光眼管理承诺。 于2022年11月，公司与C&V Tech达成一项有关TONO-i的独家分销协议。C&V Tech为一间于开发诊 断、治疗及预防青光眼的医疗器材领域具有领先地位的公司。根据该协议的条款，公司拥有于大中华登 记、进口、推广、分销、营销及出售TONO-i的独家权利。该等权利其后透过合约修订扩大至包括泰国 及马来西亚，自2024年8月起生效。 TONO-i为一款创新的眼压计，设计特点为免触式、便携及轻便。有别于传统的接触式眼压计，TONO-i 可于无需麻醉下，无痛、无感染风险地安全使用。 智通财经APP讯，兆科眼科-B(06622)发布公告，公司已向国家药品监督管理局取得TONO-i的医疗器械 注册证。 ...

Core Viewpoint - The company has received a medical device registration certificate for TONO-i from the National Medical Products Administration, marking a significant advancement in its glaucoma product portfolio [1] Group 1: Product Overview - TONO-i is an innovative, non-contact, portable, and lightweight tonometer designed for painless and infection-free use without anesthesia [1] - The device aims to address the low diagnosis and treatment rates for glaucoma in China, providing an essential tool for ophthalmologists to monitor intraocular pressure accurately and continuously [1] Group 2: Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of glaucoma diagnostic and treatment medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, which has since been expanded to include Thailand and Malaysia, effective from August 2024 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited （於英屬處女群島註冊成立並於開曼群島存續的有限公司） （股份代號：6622） 兆科眼科有限公司 自 願 性 公 告－ 向國家藥品監督管理局取得供測量眼壓的 TONO-i的醫療器械註冊證 本 公 告 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 – 1 – 關於青光眼 按 照 灼 識 諮 詢，青 光 眼 是 全 球 第 二 位 的 致 盲 因 素，是 一 種 與 高 眼 壓 導 致 視 神 經 損 傷 相 關 的 慢 性 及 漸 進 性 疾 病。眼 壓 由 眼 內 房 水 產 生 與 房 水 排 放 比 率 的 平 衡 決 定。幾 乎 所 有 的 青 光 眼 個 案 為 原 發 性 青 光 眼，通 常 可 分 為 開 角 型 青 光 眼 及 閉 角 ...